Leiming Xie
Papers
3
Total Citations
147
H-Index
3
About
Leiming Xie is at the forefront of biohybrid microrobotics, pioneering the use of living cells as active, targeted drug-delivery vehicles for cancer therapy. His research uniquely integrates oncolytic virotherapy with magnetic propulsion, creating "cell robots" that function as Trojan horses to infiltrate and destroy tumors. Xie’s most influential work, a 2022 paper on magnetic-powered Janus cell robots loaded with oncolytic adenovirus for bladder cancer, has garnered 101 citations, establishing a new paradigm for active, tumor-selective virotherapy. He further advanced the field by engineering immunogenic macrophage microrobots (32 citations) that combine magnetic navigation with multimodal cancer therapy, addressing key challenges of immune clearance and limited therapeutic scope. His 2023 study on homologous carcinoma targeting (14 citations) demonstrates the versatility of this platform, using tumor cells themselves as robotic vectors. By merging robotics, immunology, and gene therapy, Xie’s contributions are shaping the next generation of precision medicine, offering a powerful strategy to overcome the biological barriers that have long hindered effective cancer treatment.
Research Focus
Key Achievements
Top Papers
- 1
- 2
- 3